KELOWNA, British Columbia,
April 22, 2017 /PRNewswire/ --
Marapharm Ventures Inc. ("Marapharm") (MDM),(MRPHF), (2M0.F) is
pleased to announce that Marapharm has been invited by the CSE to
attend the Planet Microcap Showcase 2017, in Las Vegas on April
26-28. Linda Sampson and
Yari Nieken, directors, will
represent Marapharm. As an emerging company Marapharm will
participate in one-on-one meetings, networking and will do a
presentation to financial professionals, industry leaders,
investors and executives. "We are honored to have been invited to
participate in this event, it will give us the opportunity to share
the Marapharm story alongside other keynote speakers in this
sector," Linda Sampson CEO.
Nevada update
All ground preparation and construction grading is complete at
the site. We have altered the plans to accommodate our advanced
vertical growing technology and as a result we have experienced
some permitting delays. All permits are now ready to go, and
construction will be expedited.
In the interim the Company has brought two modular buildings
onsite which will be modified to meet Nevada
State requirements for cultivation and processing. Upon
Nevada State approval, the Company will
be positioned to apply for recreational licensing, within the time
frame of the new schedule as brought forward by the State of Nevada (July
2017). "We would like to thank the mayor of North Las Vegas, John
Lee, and Nevada state
officials for their assistance in helping us move our project
forward. We invite shareholders to visit the construction site when
in Las Vegas." Linda Sampson
CEO.
ABOUT MARAPHARM VENTURES INC.
http://www.marapharm.com
Construction photos and videos can be accessed through the
Marapharm website. Marapharms common shares are publicly traded in
Canada, under the ticker symbol
"MDM" on the Canadian Securities Exchange, and in the United States, under the ticker symbol
"MRPHF" on the OTCQB, and in Europe, under the ticker symbol "2M0" on the
FSE.
Marapharm has 300,000 square feet of medical marijuana licenses
for its land and facilities in WA and NV. About two and a half
years ago, Marapharm applied in Canada to Health Canada for a MMPR (production
and sales) license and has passed the necessary security
clearances. The application is currently in the in-depth screening
process. In September 2016, Health
Canada contacted Marapharm with a provision to amend its
application to allow for the new regulations, ACMPR.
Additional information on the operations or financial results of
Marapharm are included in reports on file with applicable
securities regulatory authorities and may be accessed through the
CSE website (http://www.thecse.com), the OTC website
(http://www.otcmarkets.com), and the SEDAR website
(http://www.sedar.com) under the profile for Marapharm Ventures
Inc.
STOCK EXCHANGES:
Neither the CSE, the FSE nor the OTCQB® has approved nor
disapproved the contents of this press release. Neither the CSE,
the FSE nor the OTCQB® accepts responsibility for the adequacy or
accuracy of this release.
FORWARD - LOOKING STATEMENTS:
Certain statements contained in this news release constitute
forward looking statements. The use of any of the words
"anticipate", "continue", "estimate", "expect", 'may", "will",
"project", "should", 'believe", and similar expressions are
intended to identify forward-looking statements. These statements
involve known and unknown risks, uncertainties and other factors
that may cause actual results or events to differ materially from
those anticipated in such forward-looking statements are based on
reasonable assumption but no assurance can be given that these
expectations will prove to be correct and the forward-looking
statements included in this news release should not be unduly
relied upon.
FOR FURTHER INFORMATION:
http://www.marapharm.com or Linda
Sampson, CEO, 778-583-4476 email info@marapharm.com